Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes

Inclusion Criteria: * Age ≥ 18 * T1D ≥ 2 years * Use of insulin pump or MDI therapy for ≥ 6 months * Current use of insulin aspart * HbA1c ≤ 70mmol/mol (8.5%) * Body mass index (BMI) ≤ 30 kg/m2 * Performs exercise ≥1 time per week Exclusion Criteria: * Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start * Professional athletes or highly active individuals ( ≥ 5 hours of exercise per week) * Known or suspected allergies to glucagon or related products * History of hypersensitivity or allergic reaction to glucagon or lactose * Allergy to the patch of the CGM devices * Patients with pheochromocytoma, insulinoma or gastroparesis * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrollment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (\>12 months since last period) are not required to use contraception) * Inability to understand the individual information and to give informed consent * Current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject * Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation